Naperville, IL -- (SBWIRE) -- 04/23/2012 -- Reportstack, provider of premium market research reports announces the addition of 'Anti-cancer Drugs Market in Japan 2011-2015' to its offering.
The Anti-cancer Drugs market in Japan is expected to grow at a CAGR of 11.1 percent over the period 2011-2015. One of the key factors contributing to this market growth is the increase in the number of cancer patients in the country. The Anti-cancer Drugs market in Japan has also been witnessing the trend of using a combination of cancer therapies for treatment. However, stringent government regulations in Japan could pose a challenge to the growth of this market.
TechNavio's report, the Anti-cancer Drugs Market in Japan 2011-2015, has been prepared based on an in-depth analysis of the market with inputs from industry experts. The report focuses on Japan; it discusses the Anti-cancer drugs market in the Japan landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors dominating this market space include Roche Pharmaceuticals Inc., Novartis International AG, Takeda Pharmaceutical Co. Ltd., Eli Lilly and Co., and AstellasPharma Inc.
Key questions answered in this report:
What will the market size be in 2015 and at what rate will it grow?
What key trends is this market subject to?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the opportunities and threats faced by each of these key vendors?
What are the strengths and weaknesses of each of these key vendors?
To view the detailed table of contents kindly visit: http://www.reportstack.com/product/64958/anti-cancer-drugs-market-in-japan-2011-2015.html